Real-World Assessment of Concomitant Medication Use in Patients Using INP104 in the United States

Presented at the AHS 65th Annual Scientific Meeting, June 15-18, 2023, Austin, Texas Authors: Gill N, Ahmed Z, Vann R, Gutierrez J, Ray S, Aurora S One sentence summary: A longitudinal, retrospective database study in the United States demonstrated that concomitant preventive and acute medication use generally decreased after patients initiated INP104 (dihydroergotamine mesylate and the […] The post Real-World Assessment of Concomitant Medication Use in Patients Using INP104 in the United States appeared first on Impel Pharmaceuticals .